Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
Sign Up to like & getrecommendations! Published in 2017 at "MedChemComm"
DOI: 10.1039/c6md00643d
Abstract: Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress… read more here.
Keywords: ros1 fusion; inhibitor ros1; ros1; cancer ... See more keywords
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Discovery"
DOI: 10.1158/2159-8290.cd-22-0968
Abstract: NVL-520, a selective macrocyclic inhibitor of ROS1, demonstrated antitumor activity in patient case studies of ROS1 inhibitor–refractory lung cancers without observed neurologic toxicities attributed to TRK inhibition. read more here.
Keywords: inhibitor ros1; nvl 520; selective trk; 520 selective ... See more keywords